

## Investor News

**Markus Georgi**  
Senior Vice President  
Investor Relations

Fresenius SE & Co. KGaA  
Else-Kröner-Straße 1  
61352 Bad Homburg  
Germany  
T +49 6172 608-2485  
markus.georgi@fresenius.com  
www.fresenius.com

January 31, 2024

### **Fresenius successfully completes divestment of fertility services group Eugin**

Fresenius has successfully completed the divestment of fertility services group Eugin. As announced in November 2023, global fertility group IVI RMA (a KKR portfolio company) and GED Capital acquired Eugin for up to €500 million including earn-outs. The transaction has received all regulatory approvals.

The divestment marks another milestone in the implementation of #FutureFresenius and is in line with the company's commitment to a simplified structure, sharper focus and accelerated performance. Furthermore, the sale proceeds will benefit Fresenius' financial flexibility.

The sale only comprises the Eugin Group. Fresenius Helios' well-established legacy business of fertility treatments in selected hospitals and outpatient centers of Quirónsalud and Helios Germany will remain with Fresenius Helios and continue to offer fertility treatments.

# # #

Fresenius SE & Co. KGaA (Frankfurt/Xetra: FRE) is a global healthcare company headquartered in Bad Homburg v. d. Höhe, Germany. In fiscal year 2022, Fresenius generated €21.5 billion in annual revenue with around 190,000 employees (excluding Fresenius Medical Care). As a healthcare company focused on therapy, Fresenius offers system-critical products and services for leading therapies for the care of critically and chronically ill patients. The Fresenius Group comprises the operating business segments Fresenius Kabi and Fresenius Helios as well as the investees Fresenius Medical Care and Fresenius Vamed. With 145 hospitals and numerous outpatient facilities, Fresenius Helios is

the leading private hospital operator in Germany and Spain, treating around 24 million patients every year. Fresenius Kabi offers drugs and medical technology for infusion, transfusion, and clinical nutrition worldwide. Fresenius was founded in 1912 by the Frankfurt pharmacist Dr. Eduard Fresenius. After his death, Else Kröner took over the management of the company in 1952 and laid the foundations for a company that today operates in around 80 countries and pursues the goal of improving people's health. The largest shareholder is the non-profit Else Kröner-Fresenius Foundation, which is dedicated to promoting medical research and supporting humanitarian projects.

For more information visit the Company's website at [www.fresenius.com](http://www.fresenius.com).

Follow us on Twitter: [www.twitter.com/fresenius\\_ir](https://www.twitter.com/fresenius_ir).

Follow us on LinkedIn: [www.linkedin.com/company/fresenius-investor-relations](https://www.linkedin.com/company/fresenius-investor-relations)

This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, the availability of financing and unforeseen impacts of international conflicts.

Fresenius does not undertake any responsibility to update the forward-looking statements in this release.

Fresenius SE & Co. KGaA

Registered Office: Bad Homburg, Germany / Commercial Register: Amtsgericht Bad Homburg, HRB 11852

Chairman of the Supervisory Board: Wolfgang Kirsch

General Partner: Fresenius Management SE

Registered Office: Bad Homburg, Germany / Commercial Register: Amtsgericht Bad Homburg, HRB 11673

Management Board: Michael Sen (Chairman), Pierluigi Antonelli, Sara Hennicken, Robert Möller, Dr. Michael Moser

Chairman of the Supervisory Board: Wolfgang Kirsch